Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
| ▸ | TBXAS1 | P24557 | 17/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939109 | 0.95 | HDAC1 (0.63) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL2638149 | 0.88 | PLOD2 (0.66) | HDAC1HDAC8TBXAS1TBXA2R | |
| SCHEMBL29450185 | 0.88 | PLOD2 (0.66) | HDAC1HDAC8TBXAS1TBXA2R | |
| SCHEMBL9549825 | 0.87 | HDAC1 (0.70) | HDAC1HDAC8TBXAS1 | |
| SCHEMBL551914 | 0.85 | HDAC1 (0.68) | HDAC1HDAC8HDAC3HDAC2TBXAS1 | |
| SCHEMBL9440256 | 0.85 | HDAC1 (0.68) | HDAC1HDAC8HDAC3HDAC2TBXAS1 | |
| Azelaic Acid SCHEMBL28673360 | 0.85 | F7 (0.71) | TBXAS1TBXA2R | |
| SCHEMBL552045 | 0.85 | HDAC1 (0.68) | HDAC1HDAC8HDAC3HDAC2TBXAS1 | |
| SCHEMBL14086334 | 0.85 | HDAC1 (0.68) | HDAC1HDAC8HDAC3HDAC2TBXAS1 | |
| Azelaic Acid SCHEMBL5982892 | 0.85 | F7 (0.71) | TBXAS1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280764-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1524262-A1 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2005-04-20 | — | — | EP | disclosed |
| US-20020115826-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2002-08-22 | — | — | US | disclosed |
| US-4511573-A | THROMBOXANE SYNTHETASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1985-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115826-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC8 9/4885HDAC3 3/4885 |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC8 9/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.